Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
77.28
+0.30 (+0.38%)
Streaming Delayed Price
Updated: 1:05 PM EDT, May 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Today 8:15 EDT
Via
Benzinga
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
Today 6:45 EDT
From
Merck & Co., Inc.
Via
Business Wire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
May 21, 2025
Via
The Motley Fool
Topics
Economy
Law Enforcement
Exposures
Economy
Legal
Product Safety
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
May 20, 2025
Via
Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
May 20, 2025
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector.
Via
Chartmill
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 19, 2025
From
Daiichi Sankyo
Via
Business Wire
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
May 18, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
May 16, 2025
From
Merck & Co., Inc.
Via
Business Wire
Decoding Merck & Co's Options Activity: What's the Big Picture?
May 15, 2025
Via
Benzinga
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
May 15, 2025
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Via
Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
May 15, 2025
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.
Via
Benzinga
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
May 15, 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via
Benzinga
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
May 15, 2025
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
May 14, 2025
From
Merck & Co., Inc.
Via
Business Wire
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
May 14, 2025
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
Via
Benzinga
FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors
May 14, 2025
Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.
Via
Benzinga
Exposures
Product Safety
3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows
May 14, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
World Trade
Exposures
Artificial Intelligence
Tariff
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?
May 14, 2025
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Assessing Merck & Co: Insights From 4 Financial Analysts
May 14, 2025
Via
Benzinga
Top S&P500 movers in Tuesday's session
May 13, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Via
Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday.
May 13, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via
Chartmill
These S&P500 stocks are gapping in today's session
May 13, 2025
Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Via
Chartmill
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
May 13, 2025
From
Merck & Co., Inc.
Via
Business Wire
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
May 13, 2025
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.
Via
Chartmill
Topics
Government
World Trade
Exposures
Political
Tariff
Dow Jones Adds 1,000 Points, Breaks 200-Day Moving Average For First Time Since April 2 Tariff Shock
May 12, 2025
The Dow surged 1,100 points after a U.S.-China trade truce, breaking above its 200-day average and fueling hopes of a market rebound — with caveats.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
May 12, 2025
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.
Via
Stocktwits
Topics
Government
Exposures
Political
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
May 12, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via
Investor's Business Daily
Topics
Government
Stocks
Exposures
Political
US Equities
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
May 12, 2025
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
MRK Q1 Earnings Call: Pipeline Expansion, Tariff Pressures, and Portfolio Diversification
May 12, 2025
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $15.53 billion. The company expects the...
Via
StockStory
Topics
Economy
World Trade
Exposures
Supply Chain
Tariff
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
May 12, 2025
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...
Via
Benzinga
Topics
Government
Exposures
Political
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.